GE HealthCare pays $945M for Sofie Biosciences to own US rights to a cancer PET agent

Medical device maker selling imaging systems and a pharmaceutical diagnostics arm that includes PET imaging agents such as FDA-approved Flyrcado.

That owning FAPI-74's US rights plus Sofie's isotope plants lets it sell more PET imaging drugs alongside its scanners as radioactive cancer care grows.

$945 million in cash, with the transaction expected to close in the first half of 2027.

GE HealthCare's radiopharma business includes Flyrcado, a PET imaging agent approved by the US FDA for detecting coronary artery disease, myocardial ischemia and heart attacks. In March 2026 it bought Montreal-based medical imaging software provider Intelerad for $2.3 billion, expanding its outpatient care reach.

Sofie Biosciences, owned by private equity firm Trilantic, develops products including radioisotopes used in PET scans and operates facilities that make and distribute them for hospitals and imaging centers. The acquisition strengthens GE HealthCare's pharmaceutical diagnostics arm by adding products used with its imaging systems and increasing exposure to the growing radiopharmaceuticals market. GE HealthCare said Sofie would continue to manufacture products for existing customers, including other radiopharma companies, after the transaction closes.

Radioactive drugs are a growing part of cancer care, and competitors' multi-billion-dollar deals signal a consolidating market.

GE HealthCare already sells the scanners; adding the drugs and the isotope supply chain increases revenue per installed system.

Completing US rights to FAPI-74 gives it full control of a late-stage cancer-detection agent it already commercializes elsewhere.

Sofie's manufacturing and distribution facilities serve hospitals and imaging centers directly, a capability GE HealthCare lacked.

For hardware makers, owning the consumable turns one-time scanner sales into recurring drug revenue — and buying the maker of an agent you already co-own is the cleanest way to lock in a geography.

As of 2026-10-05 the deal was announced, not closed: closing is expected in the first half of 2027, with Sofie continuing to manufacture for existing customers, including other radiopharma companies, in the meantime. The price — $945 million in cash — and FAPI-74's late-stage status were the disclosed terms; no revenue figures for either radiopharma business were reported.